Evidence map›Paper›PMID 38256228›Full record

ReviewInternational journal of molecular sciences2024

Magnesium and Vascular Calcification in Chronic Kidney Disease: Current Insights.

Shari J Zaslow, Gustavo H Oliveira-Paula, Wei Chen

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. The effects of elevated phosphate on the kidney - damaging the gatekeeper.Pflugers Archiv : European journal of physiology · 2026
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Soft tissue calcifications in chronic kidney disease-beyond the vasculature.Pflugers Archiv : European journal of physiology · 2025
    Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Shari J ZaslowDepartment of Medicine, Nephrology Division, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Gustavo H Oliveira-PaulaDepartment of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Wei ChenDepartment of Medicine, Nephrology Division, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Albert Einstein College of Medicine · US

Funding

Calciprotein Particles and Vascular Calcification in Patients with Chronic Kidney DiseaseR01HL172073 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Wei Chen · 2024 to 2026
$2.3M
Calcification Propensity, using Dynamic Light Scattering, to Study Vascular Calcification in Patients with Advanced Chronic Kidney DiseaseK23DK114476 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI CHEN, WEI · 2018 to 2021
$953k
Cellular Interactions in Vascular Calcification of Chronic Kidney DiseaseR03DK131246 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI CHEN, WEI · 2022 to 2023
$251k
NHLBI NIH HHS R01 HL172073NIDDK NIH HHS K23 DK114476NIDDK NIH HHS R03 DK131246
6 · The paper itself

Abstract

Magnesium (Mg) plays crucial roles in multiple essential biological processes. As the kidneys are the primary organ responsible for maintaining the blood concentration of Mg, people with chronic kidney disease (CKD) may develop disturbances in Mg. While both hyper- and hypomagnesemia may lead to adverse effects, the consequences associated with hypomagnesemia are often more severe and lasting. Importantly, observational studies have shown that CKD patients with hypomagnesemia have greater vascular calcification. Vascular calcification is accelerated and contributes to a high mortality rate in the CKD population. Both in vitro and animal studies have demonstrated that Mg protects against vascular calcification via several potential mechanisms, such as inhibiting the formation of both hydroxyapatite and pathogenic calciprotein particles as well as limiting osteogenic differentiation, a process in which vascular smooth muscle cells in the media layer of the arteries transform into bone-like cells. These preclinical findings have led to several important clinical trials that have investigated the effects of Mg supplementation on vascular calcification in people with CKD. Interestingly, two major clinical studies produced contradictory findings, resulting in a state of equipoise. This narrative review provides an overview of our current knowledge in the renal handling of Mg in health and CKD and the underlying mechanisms by which Mg may protect against vascular calcification. Lastly, we evaluate the strength of evidence from clinical studies on the efficacy of Mg supplementation and discuss future research directions.

Indexed as

Drug-Related Side Effects and Adverse ReactionsRenal Insufficiency, ChronicAnimalsHumansKidneyMagnesiumOsteogenesisMagnesiumcalciprotein particlescardiovascular diseasechronic kidney diseasedialysishydroxyapatitemagnesiummagnesium supplementationmineralizationosteogenic differentiationvascular calcificationvascular smooth muscle cell

Identifiers

PMID38256228
PMCPMC10816532
OpenAlexW4390973274

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.